• 1
    Custovic A, Chapman M. Risk levels for mite allergens. Are they meaningful? Allergy 1998;53: 7176.
  • 2
    Marks GB. House dust mite exposure as a risk factor for asthma: benefits of avoidance. Allergy 1998;53: 108114.
  • 3
    Kniest FM, Liebenberg B, Ahr A. Mattress-encasings as a barrier for mites and airborne dust. J Aerosol Sci 1992;23: S551554.
  • 4
    Kniest FM, Young E, VanPraag MC, Vos H, Kort HS, Koers WJ et al. Clinical evaluation of a double-blind dust-mite avoidance trial with mite-allergic rhinitic patients. Clin Exp Allergy 1991;21: 3947.
  • 5
    Tan BB, Weald D, Strickland I, Friedmann PS. Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet 1996;347: 1518.
  • 6
    Oosting AJ, De Bruin-Weller MS, Terreehorst I, Tempels-Pavlica Z, Aalberse RC, De Monchy JG et al. Effect of mattress encasings on atopic dermatitis outcome measures in a double-blind, placebo-controlled study: The Dutch mite avoidance study. J Allergy Clin Immunol 2002;110: 500506.
  • 7
    Cloosterman SG, Schermer TR, Bijl-Hofland ID, Van Der Heide S, Brunekreef B, Van Den Elshout FJ et al. Effects of house dust mite avoidance measures on Der p 1 concentrations and clinical condition of mild adult house dust mite-allergic asthmatic patients, using no inhaled steroids. Clin Exp Allergy 1999;29: 13361346.
  • 8
    Rijssenbeek-Nouwens LH, Oosting AJ, De Monchy JG, Bregman I, Postma DS, De Bruin-Weller MS. The effect of anti-allergic mattress encasings on house dust mite-induced early- and late-airway reactions in asthmatic patients. A double-blind, placebo-controlled study. Clin Exp Allergy 2002;32: 117125.
  • 9
    van der Heide S, Kauffman HF, Dubois AE, de Monchy JG. Allergen-avoidance measures in homes of house dust mite-allergic asthmatic patients: effects of acaricides and mattress encasings. Allergy 1997;52: 921927.
  • 10
    Terreehorst I, Hak E, Oosting AJ, Tempels-Pavlica Z, de Monchy JG, Bruijnzeel-Koomen CA et al. Evaluation of impermeable covers for bedding in patients with allergic rhinitis. N Engl J Med 2003;349: 237246.
  • 11
    Leynaert B, Neukirch F, Demoly P, Bousquet J. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol 2000;106: 201205.
  • 12
    Bousquet J, Duchateau J, Pignat JC, Fayol C, Marquis P, Mariz S et al. Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire. J Allergy Clin Immunol 1996;98: 309316.
  • 13
    Bousquet J, Bullinger M, Fayol C, Marquis P, Valentin B, Burtin B. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 1994;94: 182188.
  • 14
    Bousquet J, Knani J, Dhivert H, Richard A, Chicoye A, Ware JE Jr et al. Quality of life in asthma: I. Internal consistency and validity of the SF-36 questionnaire. Am J Respir Crit Care Med 1994;149: 371375.
  • 15
    Molen vander T, Postma DS, Schreurs AJ, Bosveld HE, Sears MR, Meyboom de Jong B. Discriminative aspects of two generic and two asthma-specific instruments: relation with symptoms, bronchodilator use and lung function in patients with mild asthma. Qual Life Res 1997;6: 353361.
  • 16
    Kiebert G, Sorensen SV, Revicki D, Fagan SC, Doyle JJ, Cohen J et al. Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol 2002;41: 151158.
  • 17
    Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol 2000;80: 430434.
  • 18
    Niemeijer NR, Fluks AF, de Monchy JG. Optimization of skin testing: II. Evaluation of concentration and cutoff values, as compared with RAST and clinical history, in a multicenter study [see comments]. Allergy 1993;48: 498503.
  • 19
    Niemeijer NR, Goedewaagen B, Kauffman HF, de Monchy JG. Optimization of skin testing: I. Choosing allergen concentrations and cutoff values by factorial design [see comments]. Allergy 1993;48: 491497.
  • 20
    Terreehorst I, Duivenvoorden HJ, Tempels-Pavlica Z, Oosting AJ, de Monchy JG, Bruijnzeel-Koomen CA et al. The unfavorable effects of concomitant asthma and sleeplessness due to the atopic eczema/dermatitis syndrome (AEDS) on quality of life in subjects allergic to house-dust mites. Allergy 2002;57: 919925.
  • 21
    Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R et al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol 1998;51: 10551068.
  • 22
    Keller SD, Bayliss MS, Ware JE Jr, Hsu MA, Damiano AM, Goss TF. Comparison of responses to SF-36 Health Survey questions with one-week and four-week recall periods. Health Serv Res 1997;32: 367384.
  • 23
    Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992;30: 473483.
  • 24
    Ware JE Jr, Keller SD, Gandek B, Brazier JE, Sullivan M. Evaluating translations of health status questionnaires. Methods from the IQOLA project. International Quality of Life Assessment. Int J Technol Assess Health Care 1995;11: 525551.
  • 25
    Ware JE Jr, Kemp JP, Buchner DA, Singer AE, Nolop KB, Goss TF. The responsiveness of disease-specific and generic health measures to changes in the severity of asthma among adults. Qual Life Res 1998;7: 235244.
  • 26
    Little GRD. Statistical analysis with missing data. New York: John Wilkey and Sons, 1987.
  • 27
    Akaike H. A new look at the statistical model identification. IEEE trans automat contr 1974;AC-19: 716723.
  • 28
    Schwarz G. Estimating the dimension of a model. Ann Stat 1978;6: 461464.
  • 29
    Beaumont F, Kauffman HF, de Monchy JG, Sluiter HJ, de Vries K. Volumetric aerobiological survey of conidial fungi in the North-East Netherlands: II. Comparison of aerobiological data and skin tests with mould extracts in an asthmatic population. Allergy 1985;40: 181186.
  • 30
    Tupker RA, DeMonchy JG, Coenraads PJ, Homan A, van der Meer JB. Induction of atopic dermatitis by inhalation of house dust mite. J Allergy Clin Immunol 1996;97: 10641070.
  • 31
    Cockcroft DW, Murdock KY, Kirby J, Hargreave F. Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine. Am Rev Respir Dis 1987;135: 264267.
  • 32
    Guyatt GH, King DR, Feeny DH, Stubbing D, Goldstein RS. Generic and specific measurement of health-related quality of life in a clinical trial of respiratory rehabilitation. J Clin Epidemiol 1999;52: 187192.
  • 33
    Peroni DG, Boner AL, Vallone G, Antolini I, Warner JO. Effective allergen avoidance at high altitude reduces allergen-induced bronchial hyperresponsiveness. Am J Respir Crit Care Med 1994;149: 14421446.
  • 34
    Platts-Mills TA, Tovey ER, Mitchell EB, Moszoro H, Nock P, Wilkins SR. Reduction of bronchial hyperreactivity during prolonged allergen avoidance. Lancet 1982;2: 675678.
  • 35
    Gotzsche PC, Johansen HK, Burr ML, Hammarquist C. House dust mite control measures for asthma. Cochrane Database Syst Rev 2001;12: CD001187.
  • 36
    Woodcock A, Forster L, Matthews E, Martin J, Letley L, Vickers M et al. Control of exposure to mite allergen and allergen-impermeable bed covers for adults with asthma. N Engl J Med 2003;349: 225236.